Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session ...Middle East

- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated - ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen - Study findings warrant further clinical...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session )

Also on site :

• Starmer will slash firms’ energy bills amid warnings net zero costs are crippling British industry
• Judge orders Kilmar Abrego Garcia’s release from jail before trial, but ICE plans to detain him
• Diamondbacks Sign James McCann